Search company, investor...
Moderna Therapeutics company logo

Moderna Therapeutics

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About Moderna Therapeutics

Moderna Therapeutics (NASDAQ: MRNA) is a biotechnology company that is focused on drug discovery and drug development based on messenger RNA. It creates synthetic mRNA that can be injected into patients to help them create their own therapies. The company was founded in 2010 and is based in Cambridge, Massachusetts.

Headquarters Location

200 Technology Square

Cambridge, Massachusetts, 02139,

United States


Missing: Moderna Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Moderna Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Moderna Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Moderna Therapeutics in 6 CB Insights research briefs, most recently on Oct 28, 2022.

Expert Collections containing Moderna Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Moderna Therapeutics is included in 4 Expert Collections, including Synthetic Biology.


Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Moderna Therapeutics Patents

Moderna Therapeutics has filed 144 patents.

patents chart

Application Date

Grant Date


Related Topics




Molecular biology, RNA, Nucleotides, DNA, Gene expression


Application Date


Grant Date



Related Topics

Molecular biology, RNA, Nucleotides, DNA, Gene expression



Latest Moderna Therapeutics News

Moderna's 'surprise' IP court order could set up a big settlement for Roivant, Arbutus — analysts

Mar 17, 2023

The big biotech signed a licensing deal with Gracell Biotechnologies last week, granting the smaller partner rights to certain patents, SEC documents show . Gracell will conduct preclinical and clinical research on the unnamed cell therapy programs and be able to bring up to five to the market. The scope of Thursday’s deal and content of the Seagen patents, however, remain a mystery for now. Neither company issued a press release about the deal and no financial terms were disclosed in the SEC filings. Representatives for Seagen and Gracell did not immediately respond to requests for comment. Keep reading Endpoints with a free subscription Unlock this story instantly and join 163,000+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Zachary Brennan Senior Editor The Centers for Medicare and Medicaid Services (CMS) late Wednesday published its first long-awaited guidance on how exactly biopharma companies will have to negotiate with the federal government when it comes to the most expensive of drugs, beginning in 2026. The 91-page guidance document sets the requirements for manufacturers of Medicare Part D and B drugs that are selected for negotiations, and CMS is soliciting feedback, before April 14, on everything from the initial offer and counteroffer exchanges between CMS and manufacturers, how the maximum fair price (i.e. the negotiated price) will be applied across different dosage forms and strengths of a drug chosen for negotiations, as well as the process for issuing monetary penalties to those violating the new law. Keep reading Endpoints with a free subscription Unlock this story instantly and join 163,000+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Senior Editor As Ultragenyx looks to use the accelerated approval pathway for an increasing number of rare disease drugs, the company has promoted Eric Crombez to EVP and chief medical officer, effective May 1. Crombez, who previously served as CMO for gene therapy and inborn errors of metabolism, joined Ultragenyx following its $138 million acquisition of Dimension Therapeutics in November 2017. Since January 2020, he’s also served in a non-voting role as industry representative on the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee. Keep reading Endpoints with a free subscription Unlock this story instantly and join 163,000+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Katherine Lewin News Reporter The FDA’s Antimicrobial Drugs Advisory Committee voted 16-1 that the benefits of Pfizer’s Covid-19 pill Paxlovid outweigh the risks in adults with mild-to-moderate illness. The vote followed hours of discussion on topics ranging from efficacy in people who have already been vaccinated or infected to drug-drug interactions (DDIs). Pfizer submitted a request to convert its EUA to a full approval back in June, but the FDA extended its review period by three months to consider additional data submitted, the company announced in December. The current PDUFA action date for a decision by the FDA is May 2023. Read More March 16, 2023 04:30 PM EDT Max Gelman Senior Editor Ahead of Keytruda’s patent cliff in 2028, Merck is trying to develop a variety of combination therapies that can extend the megablockbuster’s potential. But one of those combos just hit a snag, and it’s putting the company in damage control mode. MK-7684A, a brew of pembrolizumab (Keytruda’s chemical name) and Merck’s in-house anti-TIGIT compound vibostolimab, failed the open-label portion of a Phase II study measuring it against chemotherapy in metastatic non-small cell lung cancer, the Big Pharma announced Thursday afternoon. The regimen did not improve patients’ progression-free survival odds compared to the control and was less effective than chemo. Keep reading Endpoints with a free subscription Unlock this story instantly and join 163,000+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Beth Snyder Bulik Senior Editor GSK’s ViiV Healthcare wants to help people talk about sex. Specifically, it’s aiming to help Black women feel empowered to have sex-positive conversations and reframe discussions around HIV prevention and services in their doctor’s offices, at home and in the community. It recently debuted a series of three activity books from its “Risk to Reasons” initiative, which addresses sex and health issues for oneself, with partners and with healthcare providers. Available in both digital and hard copy versions, the ViiV team, along with partners and advocates, is distributing the purposefully thought-provoking books at the community level and in areas with greater need. Keep reading Endpoints with a free subscription Unlock this story instantly and join 163,000+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Beth Snyder Bulik Senior Editor Novo Nordisk was slapped with a two-year suspension from the UK pharma industry group, the Association of the British Pharmaceutical Industry (ABPI), on Thursday for crossing the line on its code of conduct. The suspension stems from an investigation by the Prescription Medicines Code of Practice Authority (PMCPA), which oversees the complaints procedure of the ABPI Code, over a LinkedIn post promoting a “free weight management course” by a third-party provider that was supported by Novo Nordisk. Keep reading Endpoints with a free subscription Unlock this story instantly and join 163,000+ biopharma pros reading Endpoints daily — and it's free. SIGN UP LOG IN

Moderna Therapeutics Frequently Asked Questions (FAQ)

  • When was Moderna Therapeutics founded?

    Moderna Therapeutics was founded in 2010.

  • Where is Moderna Therapeutics's headquarters?

    Moderna Therapeutics's headquarters is located at 200 Technology Square, Cambridge.

  • What is Moderna Therapeutics's latest funding round?

    Moderna Therapeutics's latest funding round is IPO.

  • How much did Moderna Therapeutics raise?

    Moderna Therapeutics raised a total of $1.961B.

  • Who are the investors of Moderna Therapeutics?

    Investors of Moderna Therapeutics include Merck & Co., Viking Global Investors, Fidelity Investments, Sequoia Capital China, Abu Dhabi Investment Authority and 18 more.

  • Who are Moderna Therapeutics's competitors?

    Competitors of Moderna Therapeutics include Ethris and 2 more.

Compare Moderna Therapeutics to Competitors

Dicerna Pharmaceuticals Logo
Dicerna Pharmaceuticals

Dicerna Pharmaceuticals is a pharmaceutical company developing RNA interference (RNAi)-based therapeutics against genetically-defined targets in multiple disease areas, including cancer. Dicerna's therapeutic approach utilizes its Dicer Substrate siRNA (DsiRNA) molecules and EnCore drug delivery technologies to silence previously undruggable disease targets, offering a potential new treatment option for patients. Dicerna delivers its DsiRNA molecules to cancer cells using its EnCore lipid nanoparticle drug delivery technology. EnCore has been specifically engineered to accumulate in tumors and mediate efficient delivery of the DsiRNAs to the RNAi machinery in the cancer cell cytoplasm. Encore particles are well tolerated and manufactured using well-established unit operations to ensure commercial scalability.

Recode Therapeutics Logo
Recode Therapeutics

ReCode Therapeutics is a genetic medicines company for mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables delivery to target organs and cells beyond the liver. The SORT LNP platform is the foundation for ReCode’s pipeline of disease-modifying mRNA and gene correction therapeutics. The company's lead programs are focused on primary ciliary dyskinesia and cystic fibrosis. Recode Therapeutics was founded in 2015 and is based in Menlo Park, California.

HDT Bio Logo

HDT Bio is a biopharmaceutical company developing drugs for immunotherapy of cancers and infectious diseases. The company was founded in 2018 and is based in Seattle, Washington.

Ethris Logo

Ethris develops mRNA therapeutics with a focus on respiratory diseases and vaccines. Its RNA technology platform helps enable the discovery, design, and development of transcript therapies that assist in restoring missing functions in patients' cells and tissues. The company was founded in 2009 and is based in Planegg, Germany.

BioNTech Logo

BioNTech (NASDAQ: BNTX) offers new immunotherapy solutions for cancer and other diseases. The Company focuses on the computational discovery and therapeutic drug platforms for developing biopharmaceuticals. It works with pharmaceutical collaborators, such as Genmab, Sanofi, Genentech, Genevant, Fosun Pharma, and Pfizer. The company was founded in 2008 and is based in Mainz, Germany.

Akcea Therapeutics Logo
Akcea Therapeutics

Akcea Therapeutics (NASDAQ: AKCA) is a late-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.